Unique ID issued by UMIN | UMIN000026163 |
---|---|
Receipt number | R000030046 |
Scientific Title | A phase I study of a 5-peptide vaccine with immune modulators for patients with refractory metastatic colorectal cancer |
Date of disclosure of the study information | 2017/03/20 |
Last modified on | 2017/08/18 09:18:08 |
A phase I study of a 5-peptide vaccine with immune modulators for patients with refractory metastatic colorectal cancer
A 5-peptide vaccine with immune modulators for patients with metastatic colorectal cancer
A phase I study of a 5-peptide vaccine with immune modulators for patients with refractory metastatic colorectal cancer
A 5-peptide vaccine with immune modulators for patients with metastatic colorectal cancer
Japan |
refractory metastatic colorectal cancer
Gastrointestinal surgery |
Malignancy
NO
To test the safety and immune responses of a 5-peptide vaccine and immune modulators in patients with refractory metastatic colorectal cancer
Safety,Efficacy
Exploratory
Pragmatic
Phase I
The safety of the immune modulators with/without 5-peptide cocktail vaccine
1) peptide-specific CTL responses and the relationship with clinical responses
2)Overall survival and preogression-free survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
1
Treatment
Medicine | Vaccine |
1)Immune modulators, composed of cyclophosphamide, metformin, celecoxib and cimetidine are administered orally for 1 week
2)Induction phase: 5-peptide cocktail vaccine weekly in combination with immune modulators are administered for 8 weeks
3)Maintenance phase: 5-peptide cocktail vaccine biweekly in combination with immune modulators are administered for 8 weeks
4)Extension phase: maintenance therapy is allowed depending on patient condition
20 | years-old | <= |
Not applicable |
Male and Female
1)standard therapy-refractory metastatic colorectal cancer
2)HLA-A24 positive patient
3)life expectancy at least 3 months
4)older than 20 years of age
5)ECOG performance status, 0,1 or 2
6)having measurable metastatic lesion
7) WBC count more than 2,000 and % of lymphocyte more than 15%
8)adequate bone marrow, liver and renal function
1)patient having double cancer
2)patient having interstitial pneumonia
3)patient having brain metastasis
4)patient having mental disorder
5)patient having uncontrollable heart disorder, pulmonary disorder or renal disorder
6)patient having bleeding tendency
7)patient having any allergic reaction to using drugs
12
1st name | |
Middle name | |
Last name | Kiyotaka OKUNO |
Kindai University Faculty of Medicine
Department of Surgery
377-2 Ohno-higashi, Osaka-sayama, Osaka
072-366-0221
okuno@surg.med.kindai.ac.jp
1st name | |
Middle name | |
Last name | Junichiro KAWAMURA |
Kindai University Faculty of Medicine
Department of Surgery
377-2 Ohno-higashi, Osaka-sayama, Osaka
072-366-0221
kawamuraj@surg.med.kindai.ac.jp
Department of Surgery, Kindai University Faculty of Medicine
Department of Surgery, Kindai University Faculty of Medicine
Other
NO
近畿大学医学部附属病院外科(大阪府)
2017 | Year | 03 | Month | 20 | Day |
Unpublished
Terminated
2017 | Year | 02 | Month | 03 | Day |
2017 | Year | 03 | Month | 20 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 05 | Month | 31 | Day |
2017 | Year | 02 | Month | 16 | Day |
2017 | Year | 08 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030046
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |